What are the current thoughts for ADT and prostate SBRT for low-Intermediate risk patients?

Although I have no strong bias regarding ADT for low-intermediate-risk prostate cancer patients receiving SBRT, the growing volume of retrospective data in the same setting with HDR brachytherapy suggests that ADT is not needed. With HDR (either monotherapy or boost), I do not use ADT for intermedia...

Its hard to argue for ADT + SBRT in "low-intermediate" risk (do you mean "favorable-intermediate"???) when this same cohort of patients has evidence supporting active surveillance and/or behavior like low-risk patients.

Just to be clear, I am using the MSKCC definition of no primary Gleason pattern ...